Open-Label Study to Evaluate the Safety and Efficacy of Two Doses of TRG-200 KIT in Patients With Refractory Overactive Bladder (OAB) : A Pilot Study
Latest Information Update: 13 Feb 2026
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Trigone Pharma
Most Recent Events
- 13 Feb 2026 New trial record